Stockreport

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]

ADC Therapeutics SA Common Shares  (ADCT) 
PDF Company Participants Nicole Riley - Head of Investor Relations & Corporate Communications Ameet Mallik - CEO & Director Mohamed Zaki - Chief Medical Officer Con [Read more]